Neuroimaging Core

神经影像核心

• 批准号: 10208706
• 负责人: KEJAL KANTARCI
• 金额: $ 83.56万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-15 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10208706
• 关键词: Alzheimer' s Disease; Biological Markers; Brain; Brain imaging; C9ORF72; Clinical; Clinical Trials; Clinical Trials Cooperative Group; Communities; Confidentiality of Patient Information; Consult; Cross-Sectional Studies; Data; Data Analyses; Dementia; Development; Diagnosis; Diagnostic; Diffusion; Disease; Ensure; Ethics; Frontotemporal Lobar Degenerations; Functional Magnetic Resonance Imaging; Funding; Future; Genes; Genetic; Goals; Image; Image Analysis; Imaging technology; Individual; Laboratories; Leadership; Light; Longitudinal Studies; MRI Scans; Magnetic Resonance Imaging; Measurement; Measures; Nerve Degeneration; Neurodegenerative Disorders; Participant; Patients; Perfusion; Pharmaceutical Preparations; Preparation; Procedures; Process; Protocols documentation; Quality Control; Recording of previous events; Research; Research Personnel; Research Project Grants; Resources; Role; Scanning; Site; Staging; Standardization; Structure; Symptoms; Testing; Work; catalyst; clinical research site; cohort; data management; data sharing; design; experience; image archival system; image processing; imaging biomarker; imaging study; innovation; innovative technologies; multimodality; mutation carrier; neuroimaging; neuropathology; programs; tool

ABSTRACT – ARTFL LEFFTDS Longitudinal FTLD: NEUROIMAGING CORE Brain imaging has taken on critical roles in dementia research, including its use for diagnosis and staging of multiple neurodegenerative disorders and enrichment of study groups for clinical trials. In the earliest stages of neurodegenerative disease, when symptoms have not yet developed, imaging and other biomarkers may be the only disease indicators that can be used to quantify drug effects in clinical trials, and imaging may ultimately guide use of approved treatments. The goal of this project is to create a neuroimaging core for the ARTFL LEFFTDS Longitudinal FTD (ALLFTD) project. The core will ensure optimal quality and efficient, innovative use of brain images collected for the project by designing and ensuring faithful application of a standardized acquisition protocol across the 19 clinical sites and promoting the application of advanced imaging technology in the FTLD field. We will design acquisition protocols that optimally utilize the scanner capabilities for the advanced sequences at each study site and allow harmonization of images across the study. All scans, along with the quality control information, will be made available to the public through the Laboratory of Neuroimaging (LONI). We will provide innovative technology and resources for understanding the contribution of MAPT, GRN or C9orf72 genes to neurodegeneration in FTLD and reliable estimates of changes in cortical volume in asymptomatic and symptomatic mutation carriers as well as patients with sporadic FTLD, in preparation for future clinical trials. We will provide resources for establishing the topographic distribution of brain structural changes across the FTLD spectrum, and work with LONI to maintain an archive of images and establish appropriate processes to ensure ethical and efficient access to the data. The Neuroimaging Core will pursue the following aims: 1) Establish and maintain a harmonized MRI acquisition protocol for acquisition and quality control of T1, FLAIR, T2, diffusion, ASL-perfusion, and task free functional MRI across 19 participating sites and supply MRI scans for research projects and the research community, while protecting patient confidentiality. 2) Operate a standardized quality control, image processing and data analysis program. 3) Supply processed cross-sectional and longitudinal data including regional cortical volume measurements and longitudinal change in cortical volume on serial MRIs for ALLFTD Projects 1 and 2, and also share these data with the research community. 4) Consult with ALLFTD and outside researchers and share research tools to facilitate use of imaging data for analysis. The leaders of this proposed neuroimaging core have extensive experience with image analysis and leadership of multicenter imaging efforts, including the Alzheimer's Disease Neuroimaging Initiative (ADNI), which set the standard for multisite imaging studies in dementia. This will help to ensure smooth conduct of the imaging activities for ALLFTD.

摘要 - ARTFL LEFFTDS纵向FTLD：神经影像核心 脑成像在痴呆研究中起着关键作用，包括用于诊断和分期 多种神经退行性疾病和用于临床试验的研究组的富集。在最早的阶段 神经退行性疾病，当症状尚未发展时，成像和其他生物标志物可能是 在临床试验中可用于量化药物作用的唯一疾病指标，成像可能 最终指导使用批准的治疗方法。该项目的目的是为 Artfl Lefftds纵向FTD（AllFTD）项目。核心将确保最佳质量和高效， 通过设计并确保忠实地应用为项目收集的大脑图像的创新使用 在19个临床部位的标准化采集方案并促进了高级的应用 FTLD领域的成像技术。我们将设计最佳利用扫描仪的采集协议 每个研究地点的高级序列的功能，并允许图像跨越整个图像 学习。所有扫描以及质量控制信息将通过 神经影像学实验室（LONI）。我们将提供创新的技术和资源以理解 MAPT，GRN或C9ORF72基因对FTLD中神经退行性的贡献以及可靠的估计值 无症状和有症状突变载体的皮质体积的变化以及患者 零星的FTLD，为将来的临床试验做准备。我们将提供资源来建立 大脑在FTLD频谱之间的大脑结构变化的地形分布，并与LONI合作维护 图像的档案并建立适当的过程，以确保对数据的道德和有效访问。 神经影像学核心将追求以下目的：1）建立和维护协调的MRI 获取和质量控制T1，Flair，T2，扩散，ASL-灌注和无任务的获取协议 跨19个参与站点的功能性MRI，并为研究项目提供MRI扫描和研究 社区，同时保护患者的机密性。 2）操作标准化质量控制，图像处理 和数据分析程序。 3）供应处理的横截面和纵向数据，包括区域 AllFTD项目的系列MRI的皮质体积测量和纵向变化 1和2，还与研究界共享这些数据。 4）咨询Allftd和外部 研究人员并共享研究工具，以促进使用成像数据进行分析。领导者 拟议的神经影像学核心在图像分析和多中心领导方面具有丰富的经验 成像努力，包括阿尔茨海默氏病神经影像学计划（ADNI），为 痴呆症中的多站点成像研究。这将有助于确保成像活动的顺利进行 Allftd。